Study to Evaluate the Safety and Efficacy of CJ-30061 in Hypertensive Patients With Hyperlipidemia

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 180 participants.

Also called NCT03639480

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 180 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT03639480
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT03639480. Randomized; quadruple masking; primary purpose treatment. Start 2017-10-13 (actual); primary completion 2018-10 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study to Evaluate the Safety and Efficacy of CJ-30061 in Hypertensive Patients With Hyperlipidemia
Condition
Hypertension
Condition
Hyperlipidemia
Intervention (Drug)
Amlodipine 10mg+Valsartan 160mg+Atorvastatin 40mg
Intervention (Drug)
Amlodipine 10mg+Valsartan 160mg
Intervention (Drug)
Valsartan 160mg+Atorvastatin 40mg
Lead sponsor
HK inno.N Corporation (class: industry)

Record details

Record id
cardio:ct-nct03639480
Content hash
4ddb6af9f463483e44e7cce7799d21ad62d9abf0637ebf4b621af18585b4fa84